Sökning: "pharmacometric"

Visar resultat 21 - 25 av 45 avhandlingar innehållade ordet pharmacometric.

1. 21. Benefits of Pharmacometric Model-Based Design and Analysis of Clinical Trials

   Författare :Kristin E Karlsson; E Niclas Jonsson; Mats O Karlsson; Anders Grahnén; Michael K Smith; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; model-based analysis; pharmacometrics; modeling; disease progression; NONMEM; SAEM; Importance sampling; repeated time-to-event; RTTCE; RCEpT; NIH stroke scale; Barthel index; internal validation; external validation; study power; study design; PHARMACY; FARMACI; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

   Sammanfattning : Quantitative pharmacokinetic-pharmacodynamic and disease progression models are the core of the science of pharmacometrics which has been identified as one of the strategies that can make drug development more effective. To adequately develop and utilize these models one needs to carefully consider the nature of the data, choice of appropriate estimation methods, model evaluation strategies, and, most importantly, the intended use of the model. LÄS MER

3. 22. Novel Pharmacometric Methods for Design and Analysis of Disease Progression Studies

   Författare :Sebastian Ueckert; Andrew C. Hooker; Mats O. Karlsson; Kayode Ogungbenro; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacometrics; optimal design; non-linear mixed effects models; degenerative diseases; Alzheimer s disease; item response theory; statistical power; Pharmaceutical Science; Farmaceutisk vetenskap;

   Sammanfattning : With societies aging all around the world, the global burden of degenerative diseases is expected to increase exponentially. From the perspective drug development, degenerative diseases represent an especially challenging class. LÄS MER

4. 23. Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients

   Författare :Rikke Meldgaard Røge; Maria Kjellsson; Niels Rode Kristensen; Søren Klim; Mats Karlsson; Roman Hovorka; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Glucose homeostasis; Type 2 diabetes; IGI model; Mechanismbased; NONMEM; pharmacometrics;

   Sammanfattning : Diabetes is a group of metabolic diseases characterized by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. Several models have been developed for describing the glucose-insulin system. LÄS MER

5. 24. Improved Methods for Pharmacometric Model-Based Decision-Making in Clinical Drug Development

   Författare :Anne-Gaëlle Dosne; Mats O. Karlsson; Rik Schoemaker; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacometrics; nonlinear mixed-effects models; confirmatory trials; residual error modeling; parameter uncertainty; sampling importance resampling; model-averaging; Farmaceutisk vetenskap; Pharmaceutical Science;

   Sammanfattning : Pharmacometric model-based analysis using nonlinear mixed-effects models (NLMEM) has to date mainly been applied to learning activities in drug development. However, such analyses can also serve as the primary analysis in confirmatory studies, which is expected to bring higher power than traditional analysis methods, among other advantages. LÄS MER

7. 25. Pharmacometric Models to Improve the Treatment and Development of Drugs against Tuberculosis

   Författare :Robin J. Svensson; Ulrika S H Simonsson; Mats O Karlsson; Andreas Krause; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacokinetics; Pharmacodynamics; Biomarkers; Rifampicin; Clofazimine; Therapeutic drug monitoring; Time-to-event; Time-to-positivity; Molecular bacterial load assay; Farmaceutisk vetenskap; Pharmaceutical Science;

   Sammanfattning : With 10 million new infections yearly, tuberculosis has a major impact on the human well-being of the world. Most patients have infections susceptible to a first-line treatment with a treatment success rate of 80%, a number that can potentially be improved by optimising the first-line treatment. LÄS MER